Figure 2.

Vancomycin and teicoplanin usage in major Hong Kong hospitals, 1997–1999. Consistent with the highest level of tertiary activity in HK (management of the vast majority of patients with complex haematological disorders and renal, bone marrow and liver transplants), in 1997, Queen Mary (QM) hospital exhibited the highest usage of glycopeptides; about 30% more than Hospital I which ranked second highest. Despite continuing the same order of tertiary activity, by 1999 corresponding QM usage had decreased to the same level as in Hospital I, but usage elsewhere increased or remained unchanged.